# Janssen Pharmaceutical K.K. clinical trials: 126 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 126 trials with Janssen Pharmaceutical K.K. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Janssen Pharmaceutical K.K.: 126 rows for $6.30, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/janssen-pharmaceutical-k-k

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 126
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 126, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 6, 2024 | NCT06295692 | A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | Janssen Pharmaceutical K.K. | Phase 3 | Active not recruiting | Generalized Pustular Psoriasis, Erythrodermic Psoriasis | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06295692) |
| October 5, 2022 | NCT05567185 | A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer | Janssen Pharmaceutical K.K. | Phase 1 | Completed | Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05567185) |
| February 16, 2022 | NCT05242432 | A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory... | Janssen Pharmaceutical K.K. | Phase 3 | Terminated | Respiratory Syncytial Virus Prevention | 2,192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05242432) |
| December 22, 2021 | NCT05167825 | A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension | Janssen Pharmaceutical K.K. | Phase 3 | Completed | Pulmonary Arterial Hypertension | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05167825) |
| December 15, 2021 | NCT05159128 | A Study of JNJ-75105186 in Healthy Japanese and Chinese Participants | Janssen Pharmaceutical K.K. | Phase 1 | Withdrawn | Healthy | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05159128) |
| September 30, 2021 | NCT05062200 | A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants | Janssen Pharmaceutical K.K. | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05062200) |
| September 9, 2021 | NCT05039710 | A Study of JNJ-75220795 in Japanese Participants | Janssen Pharmaceutical K.K. | Phase 1 | Terminated | Fatty Liver | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05039710) |
| July 15, 2021 | NCT04963725 | A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice | Janssen Pharmaceutical K.K. | Observational | Completed | Ulcerative Colitis | 137 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04963725) |
| June 30, 2021 | NCT04945733 | A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer | Janssen Pharmaceutical K.K. | Phase 2 | Terminated | Stomach Neoplasms, Esophageal Neoplasms | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04945733) |
| May 11, 2021 | NCT04882072 | A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) | Janssen Pharmaceutical K.K. | Phase 3 | Terminated | Takayasu Arteritis | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04882072) |
| May 3, 2021 | NCT04868916 | An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa | Janssen Pharmaceutical K.K. | Observational | Completed | X-Linked Retinitis Pigmentosa | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04868916) |
| March 10, 2021 | NCT04791332 | A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants | Janssen Pharmaceutical K.K. | Phase 1 | Completed | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04791332) |
| February 26, 2021 | NCT04773522 | A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma | Janssen Pharmaceutical K.K. | Phase 1 | Completed | Multiple Myeloma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04773522) |
| January 19, 2021 | NCT04713930 | A Study of JNJ-61393215 in Healthy Japanese Male Participants | Janssen Pharmaceutical K.K. | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04713930) |
| January 6, 2021 | NCT04696809 | A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma | Janssen Pharmaceutical K.K. | Phase 1/2 | Completed | Hematologic Malignancies | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04696809) |
| December 24, 2020 | NCT04683029 | A Study of Guselkumab in Participants With Systemic Sclerosis | Janssen Pharmaceutical K.K. | Phase 2 | Completed | Scleroderma, Systemic | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04683029) |
| December 21, 2020 | NCT04677530 | A Study of JNJ-40411813 in Healthy Japanese Male Participants | Janssen Pharmaceutical K.K. | Phase 1 | Completed | Healthy | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04677530) |
| November 16, 2020 | NCT04630145 | A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With... | Janssen Pharmaceutical K.K. | Phase 2/3 | Completed | Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04630145) |
| August 12, 2020 | NCT04509947 | A Study of Ad26.COV2.S in Adults (COVID-19) | Janssen Pharmaceutical K.K. | Phase 1 | Completed | Healthy | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04509947) |
| August 5, 2020 | NCT04500808 | A Study of Macitentan, in Healthy Japanese Male Participants | Janssen Pharmaceutical K.K. | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04500808) |
| July 7, 2020 | NCT04459507 | A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan | Janssen Pharmaceutical K.K. | Observational | Completed | Palmoplantar Pustulosis | 276 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04459507) |
| May 21, 2020 | NCT04397263 | A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | Janssen Pharmaceutical K.K. | Phase 3 | Completed | Crohns Disease | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04397263) |
| April 21, 2020 | NCT04354480 | A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV)... | Janssen Pharmaceutical K.K. | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04354480) |
| March 30, 2020 | NCT04325828 | A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma | Janssen Pharmaceutical K.K. | Phase 2 | Active not recruiting | Salivary Gland Neoplasms | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04325828) |
| March 12, 2020 | NCT04306302 | A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese Adults | Janssen Pharmaceutical K.K. | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04306302) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 44 |
| Phase 1/2 | 3 |
| Phase 2 | 25 |
| Phase 2/3 | 2 |
| Phase 3 | 42 |
| Phase 4 | 6 |
| Observational | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 110 |
| Terminated | 10 |
| Withdrawn | 4 |
| Active not recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Multiple Myeloma | 10 |
| Schizophrenia | 9 |
| Psoriasis | 8 |
| Pain | 7 |
| Alzheimer Disease | 6 |
| Chronic Pain | 6 |
| Neoplasms | 6 |
| Hepatitis C, Chronic | 6 |
| Hepatitis C | 5 |
| Low Back Pain | 4 |
| Recurrence | 4 |
| Arthritis, Rheumatoid | 3 |
| Prostatic Neoplasms | 3 |
| Dementia | 3 |
| Osteoarthritis | 2 |
| Dermatitis, Atopic | 2 |
| Neuralgia, Postherpetic | 2 |
| Pain, Intractable | 2 |
| Colitis, Ulcerative | 2 |
| Osteoarthritis, Knee | 2 |
| Migraine Disorders | 2 |
| Cancer Pain | 2 |
| Cognitive Dysfunction | 2 |
| Attention Deficit Disorder with Hyperactivity | 2 |
| Pain, Postoperative | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Dialysis clinics in the United States](https://specstream.ai/data/businesses/dialysis-clinics/united-states)
- [Private schools in the United States](https://specstream.ai/data/businesses/private-schools/united-states)
- [Civil rights law firms in the United States](https://specstream.ai/data/businesses/civil-rights-law-firms/united-states)
- [Paper mills in the United States](https://specstream.ai/data/businesses/paper-mills/united-states)
- [Bookkeeping firms in the United States](https://specstream.ai/data/businesses/bookkeeping-firms/united-states)
